Hit-to-Lead Identification and Validation of a Triaromatic Pleuromutilin Antibiotic Candidate
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Christoffer V Heidtmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, DK-5230 Odense M, Denmark. Hauptthemen laut MEDLINE: Diterpenes, Staphylococcal Infections, Polycyclic Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Novo Nordisk Fonden, Carlsbergfondet, Innovationsfonden.
Abstract (Originalsprache)
Herein, we report the hit-to-lead identification of a drug-like pleuromutilin conjugate 16, based on a triaromatic hit reported in 2020. The lead arose as the clear candidate from a hit-optimization campaign in which Gram-positive antibacterial activity, solubility, and P-gp affinity were optimized. Conjugate 16 was extensively evaluated for its in vitro ADMET performance which, apart from solubility, was overall on par with lefamulin. This evaluation included Caco-2 cell permeability, plasma protein binding, hERG inhibition, cytotoxicity, metabolism in microsomes and CYP3A4, resistance induction, and time-kill kinetics. Intravenous pharmacokinetics of 16 proved satisfactory in both mice and pigs; however, oral bioavailability was limited likely due to insufficient solubility. The in vivo efficacy was evaluated in mice, systemically infected with Staphylococcus aureus, where 16 showed rapid reduction in blood bacteriaemia. Through our comprehensive studies, lead 16 has emerged as a highly promising and safe antibiotic candidate for the treatment of Gram-positive bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, DK-5230 Odense M, Denmark.
- Department of Clinical Research, Research Unit of Clinical Microbiology, University of Southern Denmark, DK-5230 Odense M, Denmark.
- Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark.
- Department of Biochemistry and Molecular Biology, Research Unit of Molecular Microbiology, University of Southern Denmark, DK-5230 Odense M, Denmark.
ORCID-Profile: Christoffer V Heidtmann, Marco G Asmussen, Bala K Prabhala, Janne K Klitgaard, Thomas E Andersen, Carsten U Nielsen, Poul Nielsen
Förderung
- Novo Nordisk Fonden
- Carlsbergfondet
- Innovationsfonden
- H?rslev-Fonden
Zitieren
APA
Heidtmann, C. V., Fejer, A. R., Stærk, K., Pedersen, M., Asmussen, M. G., Hertz, F. B., Prabhala, B. K., Frimodt-Møller, N., Klitgaard, J. K., Andersen, T. E., Nielsen, C. U., & Nielsen, P. (2024). Hit-to-Lead Identification and Validation of a Triaromatic Pleuromutilin Antibiotic Candidate. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02153
Vancouver
Heidtmann CV, Fejer AR, Stærk K, Pedersen M, Asmussen MG, Hertz FB, et al. Hit-to-Lead Identification and Validation of a Triaromatic Pleuromutilin Antibiotic Candidate. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02153
BibTeX
@article{Heidtmann2024,
author = {Heidtmann, Christoffer V and Fejer, Andreas R and Stærk, Kristian and Pedersen, Maria and Asmussen, Marco G and Hertz, Frederik B and Prabhala, Bala K and Frimodt-Møller, Niels and Klitgaard, Janne K and Andersen, Thomas E and Nielsen, Carsten U and Nielsen, Poul},
title = {Hit-to-Lead Identification and Validation of a Triaromatic Pleuromutilin Antibiotic Candidate},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02153}
}
EUVIMED